[Multifocal cutaneous leishmaniasis due to Leishmania infantum under adalimumab therapy].
Schneider
P
P
Bouaziz
J D
JD
Foulet
F
F
Duong
T A
TA
Allanore
L Valeyrie
LV
Bagot
M
M
D000068879:Adalimumab; D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018314:Leishmania infantum; D016773:Leishmaniasis, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000981:Antiprotozoal Agents; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000666:Amphotericin B; D000068879:Adalimumab